DE69232323T2 - Verwendung von Adenosinantagonisten zur Vorbeugung und Behandlung von Pankreatitis und Ulcera - Google Patents

Verwendung von Adenosinantagonisten zur Vorbeugung und Behandlung von Pankreatitis und Ulcera

Info

Publication number
DE69232323T2
DE69232323T2 DE69232323T DE69232323T DE69232323T2 DE 69232323 T2 DE69232323 T2 DE 69232323T2 DE 69232323 T DE69232323 T DE 69232323T DE 69232323 T DE69232323 T DE 69232323T DE 69232323 T2 DE69232323 T2 DE 69232323T2
Authority
DE
Germany
Prior art keywords
pancreatitis
prevention
treatment
ulcers
adenosine antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69232323T
Other languages
English (en)
Other versions
DE69232323D1 (de
Inventor
Youichi Shiokawa
Atsushi Akahane
Hirohito Katayama
Takafumi Mitsunaga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/715,460 external-priority patent/US5155114A/en
Priority claimed from PH42760A external-priority patent/PH30486A/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of DE69232323D1 publication Critical patent/DE69232323D1/de
Application granted granted Critical
Publication of DE69232323T2 publication Critical patent/DE69232323T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69232323T 1991-01-29 1992-01-28 Verwendung von Adenosinantagonisten zur Vorbeugung und Behandlung von Pankreatitis und Ulcera Expired - Fee Related DE69232323T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64832091A 1991-01-29 1991-01-29
US07/715,460 US5155114A (en) 1989-01-23 1991-06-14 Method of treatment using pyrazolopyridine compound
PH42760A PH30486A (en) 1990-07-18 1991-07-09 Pyrazolopyridine compound and processes for preparation thereof

Publications (2)

Publication Number Publication Date
DE69232323D1 DE69232323D1 (de) 2002-02-07
DE69232323T2 true DE69232323T2 (de) 2002-08-08

Family

ID=27354002

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232323T Expired - Fee Related DE69232323T2 (de) 1991-01-29 1992-01-28 Verwendung von Adenosinantagonisten zur Vorbeugung und Behandlung von Pankreatitis und Ulcera

Country Status (6)

Country Link
EP (1) EP0497258B1 (de)
JP (1) JPH0558913A (de)
AT (1) ATE211384T1 (de)
CA (1) CA2060138A1 (de)
DE (1) DE69232323T2 (de)
MX (1) MX9200361A (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565566A (en) * 1987-04-24 1996-10-15 Discovery Therapeutics, Inc. N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5395836A (en) * 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5541213A (en) * 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
EP0711772A4 (de) * 1994-05-17 1996-12-04 Kyowa Hakko Kogyo Kk Verfahren zur herstellung von xanthinederivaten
US5670501A (en) * 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines
AU733316B2 (en) * 1996-10-04 2001-05-10 Kyorin Pharmaceutical Co. Ltd. Pyrazolopyridylpyridazinone derivatives and process for preparing the same
US6303624B1 (en) * 1997-03-18 2001-10-16 Fujisawa Pharmaceutical Co., Ltd. Preventives and remedies for hyperphosphatemia
CA2234342A1 (en) * 1997-04-10 1998-10-10 Kyowa Hakko Kogyo Co., Ltd. Pancreatitis remedy
WO1999067239A1 (fr) * 1998-06-22 1999-12-29 Fujisawa Pharmaceutical Co., Ltd. Composes pyrazolopyridiniques et leur utilisation comme medicaments
JP2004505048A (ja) 2000-08-01 2004-02-19 ユニバーシティー　オブ　ヴァージニア　パテント　ファウンデーション 血管新生を処理するための、選択的アデノシンａ１受容体アゴニスト、アンタゴニストおよびアロステリックエンハンサーの使用
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
DE60112330T2 (de) 2000-12-15 2006-04-13 Glaxo Group Ltd., Greenford Pyrazolopyridinderivate
US6919352B2 (en) 2000-12-15 2005-07-19 Smithkline Beecham Corporation Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
ES2227451T3 (es) 2001-03-08 2005-04-01 Smithkline Beecham Corporation Derivados de pirazolopiridina.
WO2002078700A1 (en) 2001-03-30 2002-10-10 Smithkline Beecham Corporation Pyralopyridines, process for their preparation and use as therapteutic compounds
EP1377575B1 (de) 2001-04-10 2006-07-05 SmithKline Beecham Corporation Antivirale pyrazolopyridin verbindungen
US6962914B2 (en) 2001-04-27 2005-11-08 Smithkline Beecham Corporation Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
CZ301491B6 (cs) 2001-04-27 2010-03-24 Eisai R&D Management Co., Ltd. Pyrazolo[1,5-a]pyridiny a léciva s jejich obsahem
HUP0400266A2 (hu) 2001-06-21 2004-08-30 Smithkline Beecham Corp. Imidazo[1,2-a]piridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk herpeszvírus-fertőzések megelőzésére vagy kezelésére
ES2262893T3 (es) 2001-10-05 2006-12-01 Smithkline Beecham Corporation Derivados de imidazo-piridina para su uso en el tratamiento de infeccion virica por herpes.
JP2005516916A (ja) 2001-12-11 2005-06-09 スミスクライン ビーチャム コーポレーション 抗ヘルペス薬としてのピラゾロ−ピリジン誘導体
WO2004033454A1 (en) 2002-10-03 2004-04-22 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridine derivatives
JP4859666B2 (ja) * 2003-06-06 2012-01-25 エンダセア， インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
ES2396126T3 (es) 2008-04-15 2013-02-19 Eisai R&D Management Co., Ltd. Compuesto de 3-fenilpirazol[5,1-b]tiazol
EP2320737B1 (de) 2008-08-05 2013-07-17 Merck Sharp & Dohme Corp. Pyrazolo-[1,5-a]-pyridine als mark-hemmer
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
KR20150003766A (ko) 2012-04-26 2015-01-09 브리스톨-마이어스 스큅 컴퍼니 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피리다진 유도체
DK3243826T3 (da) 2012-04-26 2020-02-03 Bristol Myers Squibb Co Imidazothiadiazol-og imidazopyrazinderivater som proteaseaktiverede receptor 4- (par4) hæmmere til behandling af blodpladeaggregation
EA201491967A1 (ru) 2012-04-26 2015-03-31 Бристол-Майерс Сквибб Компани Производные имидазотиадиазола в качестве ингибиторов активируемых протеазой рецепторов 4 (par4) для лечения агрегации тромбоцитов

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES482789A0 (es) * 1978-08-25 1980-12-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
DE3536030A1 (de) * 1985-10-09 1987-04-09 Thomae Gmbh Dr K Verwendung von benzimidazolen zur behandlung der migraene
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
AU5436790A (en) * 1989-04-19 1990-11-16 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Sulfer-containing xanthine derivatives as adenosin antagonists
GB9015764D0 (en) * 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof

Also Published As

Publication number Publication date
ATE211384T1 (de) 2002-01-15
DE69232323D1 (de) 2002-02-07
MX9200361A (es) 1992-07-01
CA2060138A1 (en) 1992-07-30
JPH0558913A (ja) 1993-03-09
EP0497258A2 (de) 1992-08-05
EP0497258A3 (en) 1993-10-13
EP0497258B1 (de) 2002-01-02

Similar Documents

Publication Publication Date Title
DE69232323T2 (de) Verwendung von Adenosinantagonisten zur Vorbeugung und Behandlung von Pankreatitis und Ulcera
DE69121827D1 (de) Verwendung von Angiotensin-II-Antagonisten zur Herstellung eines Arzneimittels zur Behandlung von Hyperuricemie
ATE175412T1 (de) Hiv-protease-inhibitoren
ATE209490T1 (de) Substanz p antagonisten zur behandlung von erbrechen
IE873125L (en) Benzimidazole derivatives
DE69129331D1 (de) Verwendung von inosittriphosphat zur zubereitung von medikamenten
DE69420229T2 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
ES2093357T3 (es) Metodo de tratamiento de la alopecia.
IT1240683B (it) Composizione farmaceutica contenente egf
IL97054A0 (en) Pharmaceutical compositions comprising buspirones for the treatment of sleep apneas
NO893256L (no) Fremgangsmaate for fremstilling av furyltiazolderivater.
FI923751A0 (fi) Hexahydrobenso/f/kinolinoner.
ATE75399T1 (de) Therapeutikum zur behandlung von magengeschwueren.
TR199900141T2 (xx) Bunama tedavisi ve/veya profilaksisi i�in form�lasyon.
DK0661058T3 (da) Anvendelse af bradykininantagonister til behandling af virussygdomme
NO922635D0 (no) Ny anvendelse av benzimidazolin-2-okso-1-karboksylsyrederivater
DE69808287T2 (de) Pharmazeutische zusammensetzungen von cinchonin dihydrochlorid
IT1216103B (it) Peptidi ad attivita' farmaceutica.
ATE175349T1 (de) Verwendung von etofibrat und pharmazeutische zusammensetzungen, enthaltend etofibrat, zur behandlung der diabetischen angio- und retinopathie
KR900007413A (ko) 에이즈 발병방지, 치료제 및 그 치료용 조성물
SE9304065D0 (sv) New compound
DE59405654D1 (de) T-lymphozyten enthaltende pharmazeutische zusammensetzung zur behandlung von infektionen
JO1519B1 (en) New compounds (new benzimidazole derivatives are effective as ulcers)
IT8919204A0 (it) Composizione per la prevenzione e la cura di parodontopatte.

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee